Company news

Achieve Life Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

March 11, 2025

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

March 7, 2025

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

March 6, 2025

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

February 9, 2025

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

January 9, 2025

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

January 6, 2025

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

December 8, 2024

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

December 2, 2024

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

October 15, 2024

Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting

October 9, 2024

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

September 30, 2024

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

August 25, 2024

Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

August 12, 2024

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

July 30, 2024

Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank

July 28, 2024

Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes

May 28, 2024

Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting

May 16, 2024

Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update

May 8, 2024

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

May 5, 2024

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update

March 27, 2024

Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

March 19, 2024

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024

March 13, 2024

Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission

February 28, 2024

Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement

February 28, 2024

Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update

November 8, 2023

Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023

October 25, 2023

Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

September 10, 2023

Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update

August 13, 2023

Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast

July 31, 2023

Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting

July 17, 2023

Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

July 10, 2023

Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

May 24, 2023

Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

May 22, 2023

Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank

May 16, 2023

Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update

May 8, 2023

Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

April 25, 2023

Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline

April 19, 2023

Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference

April 13, 2023

Achieve Life Sciences Announces Refresh to Board of Directors

March 29, 2023

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

March 28, 2023

Achieve Life Sciences Announces Granting of New Hire Inducement Award

March 16, 2023

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

March 15, 2023

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

March 7, 2023

Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

March 2, 2023

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023

March 1, 2023

Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

February 6, 2023

Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference

February 1, 2023

Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

January 8, 2023

Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation

December 20, 2022

Achieve Life Sciences Announces Private Placement of $18.9 Million

November 14, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.